Suppr超能文献

组蛋白去乙酰化酶(HDACs)表达增加以及HDAC抑制剂SAHA对前列腺癌生长和侵袭的抑制作用。

Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

作者信息

Wang Longgui, Zou Xuanyi, Berger Aaron D, Twiss Christian, Peng Yi, Li Yirong, Chiu Jason, Guo Hongfeng, Satagopan Jaya, Wilton Andrew, Gerald William, Basch Ross, Wang Zhengxin, Osman Iman, Lee Peng

出版信息

Am J Transl Res. 2009;1(1):62-71. Epub 2009 Jan 1.

Abstract

Histone deacetetylases (HDACs) are a group of corepressors of transcriptional activators and their levels of expression are potentially dysregulated in prostate cancer. Certain inhibitors of histone deacetylases show anti-tumor activity in prostate cancer cell lines. Here, we systemically studied the expression of HDACs in human prostate cancer and the suppression of prostate cancer growth and invasion by HDAC inhibitor SAHA. HDAC1-5 showed increased expression using a combination of DNA microarray, in-situ hybridization, and immunohistochemistry in benign and malignant human prostate tissue as well as RT-PCR and Western blot analysis on various PCa cell lines. Importantly, HDAC inhibitor SAHA suppressed, in particular, prostate cancer cell growth and invasion determined using cell proliferation and Matrigel invasion assays. The findings of this study show that the expression of HDACs and their associated corepressors are increased in prostate cancer in humans and HDAC inhibitor SAHA could serve as a potential therapeutic agent in prostate cancer in addition to anti-androgens.

摘要

组蛋白去乙酰化酶(HDACs)是转录激活因子的一组共抑制因子,其表达水平在前列腺癌中可能失调。某些组蛋白去乙酰化酶抑制剂在前列腺癌细胞系中显示出抗肿瘤活性。在此,我们系统地研究了HDACs在人前列腺癌中的表达以及HDAC抑制剂SAHA对前列腺癌生长和侵袭的抑制作用。通过DNA微阵列、原位杂交和免疫组织化学相结合的方法,以及对各种前列腺癌细胞系进行RT-PCR和蛋白质印迹分析,发现HDAC1 - 5在良性和恶性人前列腺组织中的表达均增加。重要的是,HDAC抑制剂SAHA尤其抑制了通过细胞增殖和基质胶侵袭试验测定的前列腺癌细胞生长和侵袭。本研究结果表明,HDACs及其相关共抑制因子在人类前列腺癌中的表达增加,并且HDAC抑制剂SAHA除了抗雄激素外,还可作为前列腺癌的潜在治疗药物。

相似文献

2
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Prostate. 2018 Mar;78(4):266-277. doi: 10.1002/pros.23467. Epub 2017 Dec 15.
6
Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Clin Epigenetics. 2018 Jul 31;10(1):100. doi: 10.1186/s13148-018-0531-y.
9
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Clin Cancer Res. 2006 Sep 1;12(17):5199-206. doi: 10.1158/1078-0432.CCR-06-0429.

引用本文的文献

1
Epigenetic insights into prostate cancer: exploring histone modifications and their therapeutic implications.
Front Oncol. 2025 Apr 28;15:1570193. doi: 10.3389/fonc.2025.1570193. eCollection 2025.
2
Systematic analysis of histone acetylation regulators across human cancers.
BMC Cancer. 2023 Aug 8;23(1):733. doi: 10.1186/s12885-023-11220-7.
4
From Therapy Resistance to Targeted Therapies in Prostate Cancer.
Front Oncol. 2022 May 24;12:877379. doi: 10.3389/fonc.2022.877379. eCollection 2022.
5
Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia.
Diagnostics (Basel). 2021 Jul 26;11(8):1346. doi: 10.3390/diagnostics11081346.
7
Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors.
Diagnostics (Basel). 2021 Mar 14;11(3):517. doi: 10.3390/diagnostics11030517.
8
Targeting Histone Modifications in Bone and Lung Metastatic Cancers.
Curr Osteoporos Rep. 2021 Jun;19(3):230-246. doi: 10.1007/s11914-021-00670-2. Epub 2021 Mar 15.
9
Loci specific epigenetic drug sensitivity.
Nucleic Acids Res. 2020 May 21;48(9):4797-4810. doi: 10.1093/nar/gkaa210.

本文引用的文献

1
Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer.
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5236-41. doi: 10.1073/pnas.0712262105. Epub 2008 Mar 20.
2
Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
Oncogene. 2008 May 15;27(22):3201-10. doi: 10.1038/sj.onc.1210983. Epub 2008 Jan 14.
3
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70.
Am J Pathol. 2008 Jan;172(1):225-35. doi: 10.2353/ajpath.2008.070065. Epub 2007 Dec 21.
4
Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
Carcinogenesis. 2006 Oct;27(10):2124-32. doi: 10.1093/carcin/bgl075. Epub 2006 May 16.
5
Histone deacetylase inhibitors: multifunctional anticancer agents.
Cancer Treat Rev. 2006 May;32(3):157-65. doi: 10.1016/j.ctrv.2005.12.006. Epub 2006 Mar 3.
8
Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase.
Mol Cell. 2005 May 13;18(4):483-90. doi: 10.1016/j.molcel.2005.04.006.
9
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
J Neurochem. 2005 May;93(4):992-9. doi: 10.1111/j.1471-4159.2005.03098.x.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验